PRIME is the European Medicines Agency (EMA) Priority Medicines scheme to support the...
- AbbVie poised to overtake Gilead as hepatitis C leader
- The influence of coagulation cascade targets in CVD
- UK bioethics panel finds human genome editing ethically acceptable
- 15% of drug compounding facilities have violated FDA regulations
- How India’s use of unapproved antibiotics could undermine global health
EMA gives PRIME status to promising Huntington’s treatment
PRIME is the European Medicines Agency (EMA) Priority Medicines scheme to support the development of medicines that meet a high unmet need.
UK seeks harmony with EU CTR as NHS and pharma stockpile drugs
The Medicines Health Products Regulatory Agency has reaffirmed its commitment to follow the European Clinical Trials Regulation System (CTR) during the Brexit transition period, between March 2019 and December 2020.
Fast and Reliable Quantification of Data
Omnian was developed for Malvern Panalytical's high-end x-ray fluorescence (XRD) spectrometer and is also available for the Epsilon 4 energy dispersive x-ray fluorescence (EDXRF) benchtop systems. This powerful combination brings together the strengths of Omnian with the ease-of-use of Epsilon 4.
Pharma air freight: what does it take to get certified?
Swissport Cargo Services has been awarded CEIV Pharma certification for pharmaceutical logistics by the International Airport Transport Association (IATA) at its Basel EuroAirport freight hub. Sally Turner speaks to IATA and Swissport, which has now received pharma logistics certification at six of its facilities, to discuss the latest requirements for freight hubs that prepare pharma products for transport by air.
AbbVie poised to overtake Gilead as hepatitis C leader
On July 27, AbbVie announced its second quarter earnings, with the strong performance by its hepatitis C virus (HCV) portfolio—$953M in Q2 and over $1.8B for H1 2018—capping a solid financial showing.
The influence of coagulation cascade targets in CVD
Cardiovascular disease (CVD) is a general term for a variety of different diseases and conditions affecting the heart or blood vessels.
UK bioethics panel finds human genome editing ethically acceptable
In a recent report, published on July 17, the UK-based Nuffield Council on Bioethics concluded that human heritable genome editing “could be ethical under certain circumstances.”
Phlexglobal Announce US and UK Phlexglobal TMF World Forums
In the ever-challenging environment of regulatory compliance, it is vital that we all keep up with the latest strategies to efficiently stay compliant and ensure your trial master files (TMF) are inspection-ready.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.